Core Viewpoint - Merit Medical Systems, Inc. reported preliminary unaudited revenue for the year ended December 31, 2024, in the range of approximately $1.355 to $1.357 billion, indicating a projected increase of about 7.7% to 7.9% compared to the previous year [2][8]. Financial Performance - The preliminary constant currency revenue for the year ended December 31, 2024, increased by approximately 8.4% to 8.6% compared to the prior year [2][8]. - The preliminary unaudited revenue for 2024 is estimated to be between $1.355 billion and $1.357 billion, with a year-over-year increase of 7.7% to 7.9% [8][10]. Upcoming Announcements - Merit plans to announce its financial results for the quarter and year ended December 31, 2024, and provide fiscal year 2025 guidance on February 25, 2025 [3][8]. - An investor conference call is scheduled for the same day at 5:00 p.m. Eastern [3][4]. Non-GAAP Financial Measure - The company uses a non-GAAP financial measure of constant currency revenue to provide insights into underlying business trends and performance, which may be useful for period-over-period comparisons [5][6]. - The constant currency revenue is adjusted for foreign exchange rates and hedging transactions, reflecting a more accurate performance measure [6][10].

Core Viewpoint - Merit Medical Systems, Inc. (MMSI) has received FDA premarket approval for its WRAPSODY Cell-Impermeable Endoprosthesis, which is expected to enhance its market position in the vascular intervention space and drive future revenue growth [20][19]. Company Summary - MMSI currently has a market capitalization of $5.72 billion, with fiscal 2024 revenue estimates at $1.35 billion, reflecting a 7.2% growth from fiscal 2023 [2]. - The WRAPSODY device is designed to improve long-term vessel patency in dialysis patients, addressing complications such as stenosis and thrombosis [12][4]. - The WRAPSODY WAVE pivotal trial showed promising results, with primary patency rates of 89.8% for AV fistula and 82.0% for AV graft patients at six months [13]. - Following the FDA approval announcement, MMSI's shares increased by 2.03% to $98.22, with a 29.9% gain over the past year compared to the industry’s 2.2% growth [10]. Industry Summary - The global hemodialysis market was valued at $76.9 billion in 2022 and is projected to reach $111.8 billion by 2032, growing at a CAGR of 3.8% [21]. - The need for improved dialysis access solutions is underscored by the prevalence of chronic cardiac diseases and end-stage renal disease, driving demand for advanced medical devices like the WRAPSODY [21][22]. - The FDA approval of the WRAPSODY device positions Merit Medical to capitalize on the growing market for vascular interventions, enhancing its competitive edge and opening new revenue streams [19].

Core Insights - Merit Medical Systems, Inc. has received premarket approval from the US FDA for the WRAPSODY Cell-Impermeable Endoprosthesis, allowing for commercialization in the USA starting in 2025 [6] - The WRAPSODY device is designed to improve long-term vessel patency in hemodialysis patients, addressing common issues such as stenosis and thrombosis [12][19] - Clinical trial results indicate high efficacy of the WRAPSODY device, with primary patency rates of 89.8% for AV fistula and 82.0% for AV graft patients at six months [18] Company Overview - Merit Medical, founded in 1987, specializes in the development, manufacture, and distribution of proprietary disposable medical devices for interventional, diagnostic, and therapeutic procedures [10] - The company employs approximately 7,200 individuals globally and serves hospitals worldwide with a dedicated sales force and clinical support team [10] Product Details - The WRAPSODY device features a unique design with a nitinol stent frame and a multi-layer structure aimed at reducing tissue accumulation and improving blood flow [7][12] - The device is indicated for use in treating stenosis or occlusion in the dialysis access outflow circuit, specifically in peripheral veins of individuals with AV fistulas and at the venous anastomosis of synthetic AV grafts [11] Market Context - In the United States, approximately 687,000 procedures are performed annually to maintain dialysis access, with nearly 100,000 involving stent placement [17] - The WRAPSODY device is expected to set a new standard of care in the treatment of vascular access complications for dialysis patients, as indicated by the positive outcomes from the WAVE trial [19]

SOUTH JORDAN, Utah, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI) ("Merit" or the "Company"), a global leader of healthcare technology, today announced the resignation of its President, Joseph C. Wright, effective January 3, 2025. The Company noted that prior to Mr. Wright's resignation, Merit had received notice of allegations regarding his conduct, which Merit's independent directors investigated with the assistance of independent counsel. The allegations were unrelated to Me ...

Core Insights - Investors in the Medical - Dental Supplies sector should consider Merit Medical (MMSI) and West Pharmaceutical Services (WST) for potential value opportunities [1] Zacks Rank and Value Scores - Merit Medical has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while West Pharmaceutical Services has a Zacks Rank of 3 (Hold) [3] - The Zacks Rank system emphasizes companies with positive earnings estimate revisions, suggesting that MMSI is likely experiencing a more favorable earnings outlook [3] Valuation Metrics - MMSI has a forward P/E ratio of 30.86, compared to WST's forward P/E of 48.47, indicating that MMSI may be undervalued relative to WST [5] - The PEG ratio for MMSI is 2.57, while WST's PEG ratio is significantly higher at 24.42, suggesting that MMSI has better growth potential relative to its price [5] - MMSI's P/B ratio is 4.56, while WST's P/B ratio is 8.51, further indicating that MMSI is more attractively valued [6] Value Grades - Based on the analysis, MMSI earns a Value grade of B, while WST receives a Value grade of D, highlighting MMSI as the more favorable option for value investors [6]

Company Overview - Merit Medical Systems, Inc. (MMSI) announced positive six-month findings from the single-arm Arteriovenous Graft (AVG) cohort of its WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal trial, which assesses the efficacy and safety of the WRAPSODY device [1][3] - The WRAPSODY Cell-Impermeable Endoprosthesis is currently not approved for commercial distribution in the United States but is available in Brazil and the European Union [2] - The device is being used in the U.S. under an Investigational Device Exemption from the FDA, with findings from the WAVE trial supporting the premarket approval application for commercial use [3] Market Position and Financials - Merit Medical has a market capitalization of $6.12 billion and a projected earnings per share growth of 11.6%, higher than the industry's 7.5% [6] - The company delivered an earnings surprise of 7.5% in the last reported quarter [6] - Following the announcement of the trial findings, shares of the company lost nearly 0.4% at closing, despite historical synergies from product launches and positive trial outcomes [5] Product Significance - The WRAPSODY device is designed to restore and extend vessel access (patency) in hemodialysis patients, which is critical for patient survival [7] - Favorable results from the AVG arm of the WAVE trial are encouraging for physicians managing AVG patients, given the historically low patency rates [8] Industry Prospects - The global hemodialysis market was valued at $76.9 billion in 2022 and is anticipated to reach $111.8 billion by 2032, growing at a CAGR of 3.8% [9] - Factors driving the market include increasing awareness of hemodialysis and the rising prevalence of chronic cardiac diseases and end-stage renal disease [9] - The positive trial outcome is expected to solidify Merit Medical's foothold in the hemodialysis market [10] Recent Developments - In September, MMSI announced positive six-month findings from the randomized arteriovenous fistula arm of its WRAPSODY WAVE pivotal trial [11] - Over the past year, shares of the company have gained 46.2%, outperforming the industry's 9.1% rise and the S&P 500's 31.6% growth [12]

Core Viewpoint - Investors are increasingly seeking growth stocks that demonstrate above-average growth potential, particularly in the financial sector, to achieve exceptional returns, although identifying such stocks can be challenging due to inherent volatility and risks [1] Group 1: Company Overview - Merit Medical (MMSI) is identified as a promising growth stock, supported by a favorable Growth Score and a top Zacks Rank [2] - The company specializes in disposable medical devices, which positions it well within the growth stock category [3] Group 2: Earnings Growth - Merit Medical has a historical EPS growth rate of 21.5%, with projected EPS growth of 11.3% for the current year, significantly outperforming the industry average of 7.5% [4] Group 3: Cash Flow Growth - The company exhibits a year-over-year cash flow growth rate of 12.2%, which is notably higher than the industry average of -5.2%, indicating strong operational efficiency [5] - Over the past 3-5 years, Merit Medical has maintained an annualized cash flow growth rate of 11.5%, compared to the industry average of 2.2%, showcasing its consistent performance [6] Group 4: Earnings Estimate Revisions - Recent upward revisions in current-year earnings estimates for Merit Medical indicate a positive trend, with the Zacks Consensus Estimate increasing by 1.6% over the past month, suggesting favorable market sentiment [8] Group 5: Investment Positioning - Merit Medical has achieved a Growth Score of B and a Zacks Rank of 2, reflecting its strong growth metrics and positive earnings estimate revisions, positioning it well for potential outperformance in the market [9]

Merit Medical Systems, Inc. (MMSI) witnessed strong momentum in the year-to-date period. Shares of the company have rallied 37.9% compared with the industry’s growth of 3.6%. The S&P 500 composite has risen 24% in the same period.With healthy fundamentals and strong growth opportunities, this Zacks Rank #2 (Buy) company appears to be a solid wealth creator for its investors at the moment.Merit Medical specializes in providing products for peripheral and cardiac interventions, targeting conditions in interve ...

Company Performance - Merit Medical (MMSI) shares have increased by 8.8% over the past month and reached a new 52-week high of $102.88, with a year-to-date gain of 34.2% compared to 4% for the Zacks Medical sector and 4.3% for the Zacks Medical - Dental Supplies industry [1] - The company has consistently exceeded earnings expectations, reporting EPS of $0.86 against a consensus estimate of $0.80 in its last earnings report on October 30, 2024, and beating revenue estimates by 1.44% [2] - For the current fiscal year, Merit Medical is projected to achieve earnings of $3.35 per share on revenues of $1.35 billion, reflecting an 11.3% increase in EPS and a 7.15% increase in revenues [3] Valuation Metrics - Merit Medical has a Value Score of C, a Growth Score of B, and a Momentum Score of C, resulting in a VGM Score of B [6] - The stock trades at 30.4X current fiscal year EPS estimates, which is above the peer industry average of 18.9X, and at 21.1X trailing cash flow compared to the peer group's average of 17.1X [7] - The PEG ratio stands at 2.54, indicating that the company is not in the top tier from a value perspective [7] Zacks Rank - Merit Medical holds a Zacks Rank of 2 (Buy) due to rising earnings estimates, meeting the criteria for investors looking for stocks with strong potential [8] Industry Comparison - The Medical - Dental Supplies industry is positioned in the top 30% of all industries, suggesting favorable conditions for both Merit Medical and its peer, Cardinal Health, Inc. (CAH) [11] - Cardinal Health has a Zacks Rank of 2 (Buy) and is expected to post earnings of $7.74 per share on revenues of $217.08 billion for the current fiscal year, with shares gaining 3.9% over the past month [10]

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the tr ...